BioSpace News Archive

Paracrine, Inc. announced today that the FDA has granted full approval of its Investigational Device Exemption (IDE) to conduct a new pivotal trial titled Adipose Derived Regenerative Cells (ADRCs) in the Treatment of Diabetic Foot Ulcers (DFUs): A Prospective, Double-blind, Multi-center, Randomized, Parallel-group Study – The “ASCEND Trial.”

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), announced today that members of its senior management team will participate in a fireside chat and one-on-one investor meetings at the virtual Evercore ISI 4th Annual HEALTHCONx conference on December 2.

Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, announced the dosing of the first subject in a Phase 1b, open-label, multi-center, dose-escalation, dose expansion clinical trial of cirtuvivint in subjects with advanced solid tumors.

Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, based on its patented biophotonic technology, announced today that enrollment and testing of patients has begun at the Department of Obstetrics & Gynecology Hospital of Fudan University located in Shanghai.

A recent article in the peer-reviewed journal International Forum of Allergy and Rhinology reported the results of a survey offered to individuals with allergic rhinitis.

BioSig Technologies, Inc. today announced that it would participate in The Benchmark Company 10th Annual Discovery One on One Investor Conference (Virtual) on Thursday, December 2, 2021.

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, reminds investors that it will host a conference call at 11:00 A.M. Eastern Time on Thursday, November 18, 2021 to provide a clinical update and discuss the latest business developments.

Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced a significant milestone: the company has shipped 1,000 of its cell analysis systems.

The Slovenian company MESI, Ltd. won the highest distinction at this year’s German Design Awards.

AstraZeneca has been granted Fast Track Designation in the United States (US) for the development of LOKELMA® (sodium zirconium cyclosilicate) to reduce arrhythmia-related cardiovascular outcomes in patients on chronic hemodialysis with recurrent hyperkalemia (HK).